Podcasts about Lymphoma

Social drivers of health such as geographic distance, travel burden, or limited availability at specialized patient centers bar many eligible patients from receiving first-line, potentially curative therapies, including chimeric antigen receptor (CAR) T-cell therapy. Community cancer centers in particular often struggle to offer CAR T, due to the extensive resources required to safely maintain a CAR T program: emergency department access, intensive care unit resources, and inpatient admission availability. In this episode, CANCER BUZZ speaks with 2026 ACCC Innovator Award winner Andrew Dalovisio, MD, Director of the Myeloma, Lymphoma, and Cellular Therapy Program at Mary Bird Perkins, about how his team successfully launched the first fully outpatient CAR T-cell therapy program for select blood cancers in the Baton Rouge region. For other community cancer centers interested in developing a similar program, Dr. Dalovisio stressed the importance of identifying both a physician and administrative champion to navigate the process in a dyad partnership. "Less than one in five patients who meet indications [for CAR T-cell therapy] even get a referral. We can talk about how wonderful all these medicines we have are, but if they're not getting to the patients that need them, [they're] not serving [their] purpose." – Andrew Dalovisio, MD Guest: Andrew Dalovisio, MD   Director, Myeloma, Lymphoma, and Cellular Therapy Program  Mary Bird Perkins Cancer Center  Baton Rouge, Louisiana Resources: ACCC 43rd National Oncology Conference 2026 ACCC Innovator Mary Bird Perkins Cancer Center Designing a Safe, Fully Outpatient CAR T-Cell Program in the Community CAR T-Cell Therapy Insights from the Field Rising to the Occasion: The Impact of Outpatient CAR T-Cell Therapy at the Froedtert & Medical College of Wisconsin Health Network  

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Krina Patel, MD, MSc As CAR T-cell therapy options expand for relapsed or refractory (R/R) multiple myeloma, comparative data may help clinicians weigh efficacy and safety when selecting treatment. One recent matching-adjusted indirect comparison of anitocabtagene autoleucel and ciltacabtagene autoleucel drew on data from the iMMAGINE-1 and CARTITUDE-1 trials to evaluate response and safety outcomes, including cytokine release syndrome, ICANS, infections, and non-relapse mortality. To learn about the findings, their clinical implications, and important limitations of the analysis, Dr. Charles Turck speaks with Dr. Krina Patel, Professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center in Houston. She also presented these data at the 2026 International Myeloma Society Annual Meeting.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Krina Patel, MD, MSc A recent analysis used matching-adjusted indirect comparisons to evaluate anitocabtagene autoleucel, teclistamab, and talquetamab for relapsed or refractory (R/R) multiple myeloma, drawing on data from the iMMAGINE-1, MajesTEC-1, and MonumenTAL-1 trials. The analysis compared efficacy and safety outcomes across these CAR T-cell and bispecific therapies, including overall response, depth of response, MRD negativity, cytokine release syndrome, ICANS, infections, and non-relapse mortality. To explore the findings, their potential clinical implications, and key limitations of these indirect comparisons, Dr. Charles Turck speaks with Dr. Krina Patel, Professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center in Houston. She also presented these data at the 2026 International Myeloma Society Annual Meeting.

INTRODUCTION:Fever of Unknown Origin, or FUO: We have all had a fever at some point—maybe from seasonal flu or a brief stomach bug—where the body turns up the heat, fights off the bug, and recovers in a couple of days. Fever is a very efficient defense mechanism to fight microorganisms by making your body a hostile environment where they cannot survive. But what happens when a fever lasts for weeks, standard tests come back normal, and usual fever reducing medications do not seem to work?We will talk about the surprising root causes, the latest imaging technology like PET scans, and what to do when a fever refuses to break. Whether you are a medical student, a healthcare professional, or simply curious about how our body's defense mechanisms work, this episode is for you. Let us get into it!Definition of Fever of Unknown Origin.A standard fever is like a smoke alarm going off when you burn toast—you quickly spot the cause, fix it, and the alarm stops. FUO is like an alarm ringing continuously for weeks, but despite searching every room, you cannot find the source of the fire.Clinical Criteria (Classic FUO):1. Temperature >38.3 C measured on multiple occasions.2. Duration of at least 3 weeks.3.Unexplained after 1 week of intensive outpatient or inpatient evaluation (or three outpatient visits).Categories of FUO.1. Classic FUO: The traditional presentation described above.2. Nosocomial (Hospital-Acquired) FUO: Fevers in hospitalized patients without infection upon admission.3. Neutropenic FUO: Fevers in immunocompromised patients (e.g., undergoing chemotherapy) with low white blood cell counts.4. HIV-Associated FUO: Fevers lasting weeks in patients with HIV, often driven by opportunistic infections like Tuberculosis or CMV, that stands for cytomegalovirus. What a mouthful!The Big Four Causes are:Infections (~30–40%): Atypical presentations of common diseases (e.g., hidden abscesses, endocarditis, tuberculosis, or tick-borne illnesses). Our priority will be to determine if this patient is having an infection, unless we get clinical manifestations that would guide us in another direction.Autoimmune & Inflammatory Diseases (~20–30%): The immune system overreacting and attacking the body's tissues (e.g., Adult-onset Still's disease, Temporal Arteritis/Giant Cell Arteritis, Lupus).Malignancies / Cancers (~10–20%): Blood cancers (Lymphoma, Leukemia) or solid tumors (Renal cell carcinoma). Infections, autoimmune/inflammatory diseases, and malignancies cover 60-90% of the causes of FUO.Miscellaneous / Drug Fevers (~10–15%): "Drug fever" caused by adverse reactions to common medications (e.g., antibiotics, anti-seizure meds), thyroid storm, or deep vein thrombosis (DVT).Modern Medicine: Advanced imaging (CT, MRI, PET scans) which have helped us diagnose cancers and abscesses much earlier. As a result, modern FUOs are increasingly driven by autoimmune conditions, non-infectious inflammatory disorders. Sometimes it feels like we solve one problem and uncover another one!Important: Some cases remain undiagnosed (up to 30–50%) and resolve without a specific label.Diagnostic Approach:Step 1: The "Detective Work" (History & Physical):● Detailed History: Travel history, animal exposure (ticks, pets), occupational hazards, social history, medication review (to exclude drug fevers), and family history.● Potential Diagnostic Clues: Looking for subtle signals (e.g., a new heart murmur, temporal tenderness, hidden skin rashes, or swollen lymph nodes).Step 2: Basic Tiered Testing:● Blood Work: CBC (complete blood count), inflammatory markers (ESR, CRP, Ferritin), comprehensive metabolic panel, blood cultures.● Targeted Serologies: HIV, viral panels, autoimmune antibodies (ANA, Rheumatoid Factor).● Initial Imaging: Chest X-ray, abdominal ultrasound.Step 3: Advanced Diagnostic Workup:FDG-PET/CT Imaging: One of the most significant updates in recent guidelines. FDG-PET/CT uses a radioactive sugar tracer to highlight areas of high metabolic activity (inflammation, infection, tumor) throughout the entire body in a single scan. FDG-PET is a functional nuclear-imaging technique that uses ¹⁸F-fluoro-deoxy-glucose (FDG) — a radioactive glucose analog — to map tissue glucose metabolism.Targeted Biopsies: Biopsying tissues guided by PET scan findings (e.g., lymph node, liver, or temporal artery)."Refractory" Fevers:Fever vs. Hyperthermia: Standard fevers are driven by the brain's hypothalamus resetting the body's thermostat upward (often mediated by prostaglandins). ● Antipyretics (acetaminophen, NSAIDs) block prostaglandin synthesis.● If a fever does not respond to antipyretics, it may indicate non-prostaglandin-mediated inflammation (e.g., severe cytokine storm, drug-induced hyperthermia, or central nervous system dysregulation).Empiric Treatment vs. Observation:● The "Hold Your Horses" Principle: Current guidelines strongly advise against starting empirical antibiotics or steroids right away in stable patients. Antibiotics can mask infections and produce false-negative culture results, while steroids can hide inflammatory signs or exacerbate hidden infections.● When to Treat Empirically: Reserved for hemodynamically unstable patients, neutropenic patients, or specific high-suspicion conditions (e.g., suspected Temporal Arteritis to prevent blindness).Diagnostic Trial: Naproxen Test (Historical & Clinical Pearl): A brief trial of naproxen can sometimes distinguish tumor fevers (which often drop sharply in response to NSAIDs) from infectious fevers, though it is used cautiously as a supportive diagnostic clue rather than a rule. So, if a patient responds to a trial of naproxen, then we can suspect a tumor as a cause of the patient's fevers. But it is not a strong recommendation.A 2019 systematic review/meta-analysis (15 studies, 582 patients) found a 94.1% success rate for naproxen in treating confirmed neoplastic fever. The test is not specific and lacks validation, but I can see the importance of knowing this: Naproxen is effective against cancer fever.FUO evaluation is a marathon, not a sprint. Re-evaluating the patient daily in the hospital for new physical clues is often more valuable than ordering endless specialized tests. I would like to emphasize that modern tools PET/CT have transformed how quickly we locate hidden inflammation. Also, let us remember that a huge proportion of undiagnosed FUOs eventually resolve spontaneously with good long-term outcomes, provided serious conditions have been systematically ruled out.Take away messages:First, FUO is a diagnostic marathon, not a sprint. Finding the cause takes patient detective work, careful daily exams, and targeted testing rather than rushing into quick fixes.Second, modern imaging like FDG-PET scans has completely transformed how we spot hidden inflammation and infection long before standard blood work gives us an answer.And finally, 'refractory' fevers require caution. If a fever is not responding to standard antipyretics, starting antibiotics or steroids right away can hide the real culprit. In stable patients, holding off and continuing the search is often the safest path.__________________Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week!References:1) David AB, Quinlan JD. Fever of Unknown Origin in Adults. American Family Physician. 2022;105(2):137-143.2) Wright WF, Stelmash L, Betrains A, Mulders-Manders CM, Rovers CP, Vanderschueren S, Auwaerter PG; International Fever and Inflammation of Unknown Origin Research Working Group. Recommendations for Updating Fever and Inflammation of Unknown Origin From a Modified Delphi Consensus Panel. Open Forum Infectious Diseases. 2024;11(7):ofae298.3) Wright WF, Durso SC, Forry C, Rovers CP. Fever of unknown origin. BMJ. 2025;388:e080847.4) Wright WF, Auwaerter PG. Fever and fever of unknown origin: review, recent advances, and lingering dogma. Open Forum Infectious Diseases. 2020;7(5):ofaa132.5) Cunha BA, Lortholary O, Cunha CB. Fever of unknown origin: a clinical approach. The American Journal of Medicine. 2015;128(10):1138.e1-1138.e15.6) Nazar AH, Naswa N, Sharma P, et al. Spectrum of 18F-FDG PET/CT findings in patients presenting with fever of unknown origin. American Journal of Roentgenology. 2012;199(1):175-1851) Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/. Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week!

Blood cancer symptoms can be easy to dismiss as everyday illnesses, or in Karen Frenkiel's case, even pregnancy symptoms. Karen was diagnosed with lymphoma just a few days after giving birth, after months of breathlessness and a persistent cough. Professor Miles Prince explains why blood cancers can be difficult to detect early, and what warning signs people should look out for.

In this week's episode, Blood editor Dr. James Griffin interviews Dr. Jianxiang Wang from the National Clinical Research Center for Blood Diseases and the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College in Tianjin, China, on his latest article published in Blood titled "Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia." In this prospective phase 2 study, 167 adolescents and adults (aged 14-60 years) with ND Ph− ALL received a course of venetoclax combined with pediatric-inspired chemotherapy, to determine the results of this treatment on MRD negativity.

This week we wrap up our two-part CLL update by turning to relapsed and refractory disease. We pick up with the 68-year-old man from Part 1, now a year out from frontline therapy and showing signs of relapse. We cover when relapse actually needs treatment, the history of BTK inhibitor resistance and why BTK mutation testing matters, and how to sequence therapy now that BTK inhibitors and venetoclax have both moved into the frontline. From there we get into venetoclax retreatment, the pirtobrutinib data from BRUIN CLL-321 and the new BRUIN CLL-322 triplet trial, the real-world CAR T experience that is changing how we think about cell therapy in CLL, bispecific antibodies, and the emerging class of BTK degraders. As always, if you haven't heard the earlier episodes in this series, start there first.If you haven't done so, be sure to check out our original CLL Series and our CLL Updates Part I episode as this update will draw on concepts covered previously!**This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, click here! Be sure to use our SPECIAL TFOC code TFOC40 to save 40% off registration.** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube

In this episode of the Oncology Brothers podcast we had a chance to discuss the current treatment landscape for diffuse large B-cell lymphoma (DLBCL) with Dr. Mazyar Shadman, from the Fred Hutch Cancer Center.   We dived deep into frontline treatment options, including R-CHOP and polatuzumab-based regimens, and explored how to effectively risk stratify patients using the International Prognostic Index (IPI) score and the Hans algorithm. Dr. Shadman shared insights on the use of CAR T-cell therapy in both early and late relapsed settings, discussing the differences between axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and the importance of bridging and holding therapies.   Key topics covered in this episode: Frontline treatment options for DLBCL The role of polatuzumab in early-stage disease Treatment paradigms for advanced-stage DLBCL CAR T-cell therapy: who should receive it and when The importance of community and tertiary care partnerships in improving patient access to innovative therapies   Join us for an informative discussion that highlights the evolving landscape of DLBCL treatment and the critical role of collaboration in oncology care.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o   Follow us on social media: X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and share your thoughts in the comments! #DLBCL, #CARTtherapy, #RCHOP, #Polatuzumab, #OncologyBrothers

Listen to JCO's Art of Oncology article, "When Survival Separates" by Dr. Courtney Hall, who is a Vanderbilt University School of Nursing and a Pediatric Critical Care Nurse Practitioner at Vanderbilt University Medical Center. The article is followed by an interview with Hall and host Dr. Mikkael Sekeres. Hall reflects on friendship, survivorship, and the impossible tension of learning to live after cancer while grieving. LINK TO FULL TRANSCRIPT

Send us Fan MailA diagnosis of cancer changes how people think about their health, their future, and their everyday lives. For people diagnosed with blood cancers such as Waldenström macroglobulinemia or diffuse large B-cell lymphoma (DLBCL), the path from diagnosis through treatment and remission can bring both relief and ongoing uncertainty.In this episode of the Everyone Dies podcast, we talk with Karen Wolfe, a nurse practitioner about what it means to live after a lymphoma diagnosis, including the experience of receiving treatment with R-CHOP chemotherapy and transitioning into remission.For many cancer survivors, completing treatment does not mean leaving cancer completely behind. Follow-up appointments, scans, changes in the body, and concerns about recurrence can become part of a new reality. Many survivors describe learning how to balance gratitude for remission with the uncertainty of not knowing what the future holds.Learn the emotional impact of living with a cancer history, why uncertainty is a common experience after treatment, and strategies survivors use to regain their health, confidence and focus on what matters most. https://bit.ly/4rlUXvcThis episode explores:What Waldenström macroglobulinemia and diffuse large B-cell lymphoma are How treatments such as R-CHOP are used for aggressive lymphomas Why remission can bring both relief and new concerns The emotional adjustment after cancer treatment ends Living with follow-up care and the possibility of recurrence Cancer changes the story, but it does not have to define the whole story. Every day is a gift.Timestamps:00:00 - Introduction: Cancer, Recovery, and Resilience01:05 - Adaptive Wellness: High-Protein Cottage Cheese Dip Recipe01:44 - Mindful Support: What Is a Buddhist Chant List & How to Request One09:14 - Interview: Surviving Lymphoma & Living with Uncertainty with Karen Wolfe, NP14:38 - Karen's Self-Prescribed "Cancer Rehab Program"24:04 - Where Does Your Resilience Come From?38:23 - Episode Wrap-Up & Resources #LymphomaAwareness #CancerSurvivorship  #BloodCancerAwareness  #LifeAfterCancer  #LymphomaSurvivor Support the show

In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Joshua Brody, MD, the director of the Lymphoma Immunotherapy Program at the Mount Sinai Tisch Cancer Center and a faculty member of the Icahn Genomics Institute in New York, New York.Their discussion centered on the rapidly evolving treatment landscape for B-cell non-Hodgkin lymphomas, highlighting a wave of recent advances across frontline and relapsed diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) management. Drs Park and Brody framed this current era as one of unusually fast progress after decades of failed attempts to improve upon R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone).A major focus was the phase 3 frontMIND trial (NCT04824092), which added tafasitamab-cxix (Monjuvi) and lenalidomide (Revlimid) to R-CHOP in patients with frontline DLBCL. Dr Brody discussed the significant progression-free survival benefit with the experimental combination that extended across patient subgroups rather than being confined to patients with activated B-cell–like or non–germinal center disease, with only a modest increase in the rate of high-grade febrile neutropenia. He contextualized this against earlier trials in the DLBCL space.The discussion then turned to relapsed disease, where Dr Brody described the benefits of CAR T-cell therapy over stem cell transplant and reviewed bispecific antibody/chemotherapy combinations, including glofitamab-gxbm (Columvi) and epcoritamab-bysp (Epkinly) plus gemcitabine and oxaliplatin. He also emphasized the importance of clinical trials.Drs Park and Brody also explored the evolving MCL treatment paradigm, highlighting glofitamab's complete remission rate and the FDA approval of the BCL-2 inhibitor sonrotoclax (Beqalzi), alongside strategies to mitigate cytokine release syndrome and tumor lysis syndrome. The conversation concluded with a look at emerging therapies, including CD19-directed bispecific antibodies and in vivo CAR T-cell therapy delivered via viral and mRNA lipid nanoparticle vectors.

In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Mariateresa Fulciniti and Angelo D'Alessandro on their latest articles published in Blood. Dr. Fulciniti, of the Dana Farber Cancer Institute, discusses the development of "PKMYT1 is a targetable vulnerability in del(17p) high-risk multiple myeloma" starting from the question, "Is 17P loss simply a prognostic marker, or does it create specific vulnerabilities that we can therapeutically exploit?" Then, Dr. D'Alessandro, of the University of Colorado, discusses "The red blood cell proteome and interactome identify a Band 3–BLVRB axis regulating hypoxic metabolic adaptation." His team began by asking, "What's in a red blood cell? How many proteins are there, and how can we confidently claim that these now several 1000s of proteins in opposite excess are indeed proteins within red blood cells are not coming from contaminants?" Both studies describe how deep molecular profiling can uncover specific, potentially targetable biological dependencies or interaction axes that may enable more precise, mechanism‑based therapeutic strategies.

This week we kick off a two-part update to our CLL series, covering what has changed in frontline management since our original episodes. Using the case of a 68-year-old man with newly diagnosed, symptomatic CLL, we revisit the essential steps before treatment: confirming an indication to treat, ruling out Richter's transformation, and risk stratification, with the history behind FISH cytogenetics, IGHV status, and the CLL-IPI. We then trace how continuous BTK inhibitors and fixed-duration venetoclax-obinutuzumab displaced chemoimmunotherapy, before digging into the trials reshaping practice in 2026: AMPLIFY, SEQUOIA Arm D, and CLL17. Along the way, we cover the open questions for TP53-aberrant disease and why MRD, although prognostic, is not yet a reliable guide for treatment decisions with novel agents. If you haven't done so, be sure to check out our original CLL Series, as these updates will draw on concepts covered previously!**This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, click here! Be sure to use our SPECIAL TFOC code TFOC40 to save 40% off registration.** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube

#cats #catlife #meow #september #AI #DEI

Send us Fan MailMorning Prayers (Shout for joy to God; Confess / Forgive; Children; Battling diseases / Lymphoma; Those Who Are Grieving; For Each Other; Open Our Eyes...)Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peaceaimingforjesus.comYouTube Channel https://www.youtube.com/@aimingforjesus5346Instagram https://www.instagram.com/aiming_for_jesus/Threads https://www.threads.com/@aiming_for_jesusX https://x.com/AimingForJesusTik Tok https://www.tiktok.com/@aiming.for.jesus

A treatment exists that can cure aggressive lymphoma after chemotherapy has failed. Only about two in ten eligible patients receive it. Manali Kamdar is clinical director of lymphoma services at the University of Colorado Anschutz, and Paolo Strati is an associate professor of lymphoma and myeloma at MD Anderson Cancer Center. This episode is based on their article "CAR-T therapy can cure cancer. Why is it so underused?" published on KevinMD. You will hear what this therapy asks of a patient, from cell collection through the wait for manufacturing to the weeks spent living near a treatment center. They walk through the barriers a stakeholder summit identified, including the two-week payer authorization that runs while the cancer grows, the small number of accredited centers, and the myth that eligibility works like transplant eligibility. Press play to hear why they say a relapse should trigger a referral, and why they measure success by who can deliver this treatment rather than who receives it. This episode is brought to you by ModMed. Welcome to your new AI-Powered Practice from ModMed. We're transforming specialty care by embedding AI Assistants across your entire workflow. Our all-in-one platform of EHR, patient engagement, practice management, and RCM helps reduce repetitive work while keeping you firmly in control. Trained on de-identified data from nearly a billion patient encounters, this isn't just smarter software. It's a new way of working for specialty medicine, more efficient and more connected to the patient experience. Start building your AI-Powered Practice at modmed.com. VISIT SPONSOR → https://www.modmed.com/ SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast

How do you start an influencer marketing agency at 17 whilst battling stage three Hodgkin's lymphoma, scale it to 7-figures and sell it for millions by 24? Suhit Amin did exactly that.WATCH THE FULL PODCAST NOW ON YOUTUBEIn this episode, host James Burtt sits down with Suhit Amin, founder of Saulderson Media, to deconstruct the tactical playbook behind building an influencer marketing agency from scratch, winning clients with cold outreach on LinkedIn, doubling revenue with the right advisor, and navigating the full M&A process to a multi-million pound exit to Journey Further.If you want to understand how to build an agency from scratch, how to sell your business in the UK, or how to turn cold outreach strategy into compounding revenue - this is your blueprint. In This Episode You'll Learn:How Suhit turned an MCN sub-network into a talent management business making £100k in 6 months at 16The cold LinkedIn DM system he used when LinkedIn was quiet - and why manual reps beat automation earlyWhy talent management evolves into an influencer marketing agency for higher margins and scaleThe exact M&A process: from teaser and information memorandum to 5 offers, due diligence, and the 24-hour wait for money to landWhy he chose a lower multiple from Journey Further over a higher US offer and what founders get wrong about business brokers and valuationConnect with Suhit Aminhttps://www.suhitamin.com/Want more from Building The Brand? Connect here:https://buildingthebrand.co.uk/newsletterKey Moments: 0:00 - Introduction: How a 17-Year-Old Built a 7-Figure Influencer Marketing Agency 02:31 - Why Starting a Business Young Was Suhit Amin's Unfair Advantage 04:11 - From Gaming Videos to 37K Subscribers: Learning YouTube MCNs and Sub-Networks 07:04 - Why Talent Management Beat Being a Creator: Spotting the MCN Decline 09:40 - How to Start an Influencer Marketing Agency From Scratch With 5 Clients 15:35 - Cold Outreach Strategy That Worked: Turning LinkedIn DMs Into Revenue 19:25 - Consistency & Manual Reps: Why Volume Beats Automation When Starting Out 31:47 - Thinking Like a Founder: Why He Always Planned to Sell His First Business 37:18 - Doubling Revenue in 12 Months: How Advisor Simon Penson Restructured the Agency for Sale 44:15 - How to Sell Your Business: The Full M&A Process, Due Diligence & Keeping It Secret 53:54 - Choosing the Right Buyer: Why He Took a Lower Offer From Journey Further 01:04:03 - What Happens When the Money Lands: Telling the Team and Calling His Parents 01:26:14 - Battling Stage Three Hodgkin's Lymphoma at 16 While Starting a Business 01:36:26 - How Cancer Changed His View on Business, Risk and ResilienceIn this show we answer: What is this episode about? This episode of Building The Brand features Suhit Amin explaining how he built and sold a 7-figure influencer marketing agency (Saulderson Media) before age 25, detailing his cold outreach on LinkedIn, transition from talent management to influencer marketing, and the step-by-step process to sell a business including valuation, buyer outreach, and due diligence.Who is Suhit Amin? Suhit Amin is a UK entrepreneur who founded influencer marketing agency Saulderson Media at 17, scaled it to over £100k revenue in six months, doubled revenue with consultancy Scaled, and achieved a multi-million pound exit to Journey Further - all after undergoing chemotherapy for Hodgkin's lymphoma at age 16.How did Suhit Amin get clients for his influencer marketing agency? He used cold outreach on LinkedIn, identifying brands working with similar creators, connecting with marketing managers, and moving conversations from DMs to calls. He posted daily when LinkedIn was unsaturated and treated outreach like volume-based reps to learn what messaging converts.

Mark Mateya, a Carlisle, Pennsylvania attorney and former studio musician, was diagnosed with large B-cell lymphoma after a routine biopsy on a small arm growth came back malignant. After a rocky first appointment with an oncologist who initially confused his chart with another patient's and warned that forgoing chemo would be "suicide," Mark declined chemotherapy and found Chris Wark's Square One program and Healing Strong. He shifted to a whole-food, plant-based diet with juicing, reduced stress by selling his law practice (while staying on part-time), and pursued a mix of therapies including RGCC/SOT (a blood-based treatment through a lab in Greece) and multiple visits to the Immunity Therapy Center in Tijuana. He's candid that he does not have a formal NED diagnosis, but reports his circulating tumor cell count has dropped from 2.8 to 1.4 over roughly three and a half years. Mark credits his faith and connection with fellow Healing Strong leader Karen McKeon/Maxson for keeping him grounded early on, and now leads a Healing Strong group in Carlisle, where he originated the "Heal-a-Thon" fundraiser (modeled loosely on Penn State's THON) to raise money and awareness for the organization. The episode closes with his message to newly diagnosed listeners: they are not alone, cancer is not a death sentence, and they have time to think, pray, and take responsibility for their health.HealingStrong's mission is to educate, equip and empower our group leaders and group participants through their journey with cancer or other chronic illnesses, and know there is HOPE. We bring this hope through educational materials, webinars, guest speakers, conferences, community small group support and more.Please take advantage of our FREE resources below to help you along your health and healing journey:Support Group DirectoryHolistic Curriculum - Participant GuideSupport Our Mission - DonateAdditional Health ResourcesListen to Previous EpisodesWebsite: healingstrong.org

In this podcast Dr Caroline Leek shares thoughts and insights for parents with cancer when communicating with children and young people, from as young as three to 18 and above. She discusses how those difficult conversations might be prepared for and started and how having age-appropriate, but honest, conversations can help children and young people understand and cope better. She covers different stages, from diagnosis, through times in hospital having treatment, and considering end of life. Caroline believes that communication is key and can take many forms, but that these are conversations children need. Caroline is the director of Fruitfly Collective, a charity supporting parents living with cancer, and children affected by parental cancer. Lymphoma Voices is a series of podcasts for people living with lymphoma, and their family and friends. In each podcast, we are in conversation with an expert in their field, or someone who has been personally affected by lymphoma, who shares their thoughts and experiences. Lymphoma Action is the only charity in the UK dedicated to supporting people affected by lymphoma. We are here to make sure that everyone affected by the condition receives the best possible information, support, treatment and care. Our services include a Freephone helpline, support group network, Buddy Service, medical information, conferences for those affected by lymphoma, and education and training for healthcare professionals. We would like to thank all of our incredible supporters whose generous donations enable us to offer all our essential support services free of charge. As an organisation we do not receive any government or NHS funding and so every penny received is truly valued. From everyone at Lymphoma Action and on behalf of those affected by lymphoma, thank you. For further information visit: www.lymphoma-action.org.uk

In this months Cancer Prevention segment, Matt Brooks and Courtney Maxson, Senior Public Health Educator from the Cortland County Health Department discuss different types of cancers and how to prevent[Read More...] The post September is the Awareness Month for Leukemia, Lymphoma, Ovarian, Prostate, Thyroid, Gynecologic, and Childhood Cancer appeared first on X101 Always Classic - WXHC.com.

Shengjie Li, Jiazhen Cao, Jun Ren, Kun Chen, Jianing Wu, Yingzhu Li, Yunxiao Song, Chengxun Li, Wenjun Cao, Ming Guan. Tumor-Derived HAVCR1 As a Reliable Fluid Biomarker for the Diagnosis of CNS Lymphoma. Clin Chem 2026; 72(8): 880–92.  https://doi.org/10.1093/clinchem/hvag036

This week's pod has everything: 1. DDI information and dosing for daraxonrasib, now FDA approved and commercially available for pancreatic cancer 2. A new standard of care (?) in HER(+) gastric cancers, and more nuance on HER2 positivity. And lots of diarrhea. 3. The largest RCT in primary CNS lymphoma Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

In this week's episode, Blood editor Laurie Sehn interviews Drs. Efstathios Kastritis and Lucia Chen on their latest articles published in Blood. Dr. Kastritis shares insights and results from the final survival analysis of the ANDROMEDA trial, which determined that adding daratumumab to cyclophosphamide, bortezomib, and dexamethasone improves hematologic responses and overall survival in newly diagnosed AL amyloidosis.  Dr. Chen elaborates on the key benefits of Ikaros degradation for reducing T-cell dysfunction in MM patients: Ikaros degradation by mezigdomide enhances anti–B-cell maturation antigen CAR-T and bispecific TCE therapy efficacy in vitro and in vivo. Featured Articles: Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone for Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis | Efstathios KastritisIkaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies | Lucia Chen

Treatment options for patients with lymphoma are rapidly evolving. In this podcast episode, Alex F. Herrera, MD, and Marc Hoffmann, MD, discuss cereblon E3 ligase modulators (CELMoDs) as potential treatment options for patients with aggressive diffuse large B-cell lymphoma and follicular lymphoma, with a focus on golcadomide, an investigational, oral, first-in-class CELMoD therapy. Topic areas covered include:  Biologic and clinical rationale for the use of CELMoD therapy in lymphoma patients Emerging clinical trial data on golcadomide alone and in combination with other regimens Real-world expectations for incorporating CELMoD-based therapies into community lymphoma care settings such as efficacy, patient selection, and toxicity management strategies Presenters: Alex F. Herrera, MD Chief, Division of Lymphoma Professor, Department of Hematology and Hematopoietic Cell Transplantation Director, Toni Stephenson Lymphoma Center City of Hope Duarte, California Marc Hoffmann, MD Director, Lymphoma Program Medical Director, Lean and Quality Improvement Associate Professor Division of Hematologic Malignancies and Cellular Therapeutics University of Kansas Cancer Center Kansas City, Kansas Content based on an online CME program supported by an educational grant from Bristol Myers Squibb. Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Link to CME: Claim Credit Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Joshua Hill and Jeffery Weitz on their latest articles published in Blood. Dr. Hill and Dr. Michaelis discuss the evolving landscape of infection risk in adults receiving bispecific antibody therapies for advanced B‑cell malignancies. They explore how these risks differ from those seen with allogeneic transplant, CAR T‑cell therapy, and traditional CD20‑directed antibodies, and touch on emerging approaches such as trispecific antibodies and evolving strategies for supportive care, including immunoglobulin replacement. In the second half of the episode, Dr. Michaelis is joined by Dr. Jeffrey Weitz to discuss new insights into the role of histidine‑rich glycoprotein in hemostasis. Their conversation delves into HRG's interactions with key platelet receptors, its behavior in inflammatory states like sepsis and COVID‑19, and how these observations may reshape thinking about thrombosis risk and future therapeutic approaches.Featured Articles: How I prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies | Joshua Hill, MDHistidine-rich glycoprotein modulates platelet adhesion and aggregation by binding to GPIbα and GPIIb/IIIa | Jeffery Weitz, MD

Could one of the most widely used herbicides in America be connected to rising rates of cancer? In this episode, we explore the growing body of research surrounding glyphosate, non-Hodgkin lymphoma, leukemia, and cancer rates across the United States.We take a closer look at Iowa and other agricultural states, where heavy glyphosate use overlaps with elevated rates of certain cancers, and discuss what researchers have found about glyphosate exposure and blood cancers. We also examine CDC biomonitoring data showing how widespread glyphosate exposure is among Americans, including children.You'll learn about the potential mechanisms researchers are investigating, including oxidative stress, DNA damage, immune dysfunction, inflammation, and gut microbiome disruption, and why reducing unnecessary pesticide exposure may be an important part of a long-term approach to health.In this episode:Glyphosate use across the United StatesIowa, agricultural regions, and cancer ratesGlyphosate and non-Hodgkin lymphomaThe research on glyphosate and leukemiaCDC findings on glyphosate exposure in adults and childrenHow glyphosate may contribute to oxidative stress and inflammationPotential effects on the gut microbiome and immune systemPractical ways to reduce everyday pesticide exposureIf you've ever wondered how environmental chemicals may influence cancer risk, immune health, and chronic disease, this episode is for you.Save 15-30% OFF my favourite protein with code 'MARLA': https://www.equipfoods.com/MARLAClearly Filtered water filters (10% off with this link): https://clearlyfiltered.com/WHOLISTICHOMEOPATHBeef organ sticks and beef tallow(code 'MARLA'): https://lineageprovisions.com/MARLAWork with me: https://holisticspring.com/contact

In this week's episode, Blood editor Dr. James Griffin interviews Drs. George Goshua, Gerd Blobel, and Paul Kaminski on their latest articles published in Blood. Dr. Goshua elaborates on the background and then insights from "Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis". This analysis provides valuable guidance for clinicians, patients, and health systems as they consider treatment choices. However, as concluded in the accompanying Blood Commentary, the true measure of success is not which therapy “wins” the economic argument, but whether each patient receives the therapy best suited to their clinical needs and values. Then, Drs. Gerd Blobel and Paul Kaminski share "Dissecting polycomb complexes for enhanced fetal hemoglobin production", which utilizes a comprehensive CRISPR-based screen to interrogate the components of these repressive complexes and identified a single protein domain in EZH2, a subunit of PRC2, as a potential therapeutic target. They demonstrate that inhibition of the domain encoded by exon 14 of EZH2 selectively derepresses fetal hemoglobin expression, raising the possibility of developing drugs that specifically target this domain to treat hemoglobinopathies.

On this episode, Joel is joined by an inspiring man whose cancer diagnosis became his determination to live a more fruitful life. His name is Steve Garraty, a Salesforce Vice President of Sales and author of the book Greatfruit, that is equal parts memoir and motivation. After surviving Stage III Hodgkin's Lymphoma at just 18 years old, he turned a life-altering challenge into a lesson in resilience. Because sometimes the hardest chapter in your life is actually the one that changes the entire story.Website: https://stevegarraty.com/ Instagram: https://www.instagram.com/stevegarratyauthor/ Facebook: https://www.facebook.com/stevegarratyauthor/Check out the conversation on YouTube: https://youtu.be/a_wL3ka_fbg

It's the last party of the weekend and we have Stacia King Sakya live in the studio! Check out the Love for Lymphoma event at Tractor Wells park on September 5th from 2pm to 9Pm! lots of live music, classic cars and vendors to check out all for a good cause!

I love any new tool that can make my life as a veterinarian easier and get better outcomes for my patients, so when I first heard about IDEXX's new CancerDx test I was excited, but I had questions! Like, how is a cancer screening test useful to my patients, how reliable is it, why can't I just use FNA, and how am I going to incorporate it into my workflows?In this episode I chat to oncologist Dr Sandra Nguyen to find out how she thinks about this test for her patients, and where it fits into our lives as general practitioners. We cover:A genuinely memorable way to finally keep sensitivity and specificity straight The advertised numbers for Cancer Dx, and how that compares to FNA cytologyThe two clinical scenarios where Dr Sandra finds it most useful: the vaguely "cancery" dog, and annual screening in at-risk breedsWhy you should keep those slides on the shelf when owners are undecided about chemoWhat to actually do with a positive result in a happy, healthy dogIf this is the kind of clinical content you want more of, our full library of case-based CE lives at ⁠https://thevetvault.com⁠. Want to join us on a ski lift? Vets On Tour is where CE happens in ski boots, saunas, and the occasional conference room. Come find us at https://vetsontour.com/

In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Matthew Frank and Jieqing Zhu on their latest articles published in volume 147 issue 22 of Blood. Dr. Frank discusses "How I treat HLH-like toxicities after immune effector cell therapy", in which the two cases presented emphasize the need for early identification, the use of anticytokine therapy with either emapalumab or ruxolitinib when organ toxicities worsen despite conventional CRS-directed treatment, and the need for ancillary supportive care as central to success. Dr. Zhu shares insights from "Structural Basis of HPA-1 a Alloimmunization in FNAIT and Allosteric Regulation of Integrin Conformation" where they probed the structure-function relationships underpinning interactions of alloantibodies against the most common target, human platelet antigen 1a (HPA-1a). Their data can help explain why some alloantibodies cause severe hemorrhagic FNAIT while others result in milder, asymptomatic thrombocytopenia.

Bethany Smith is a fighter.  Almost immediately after surviving Hodgkin lymphoma, she was diagnosed with metastatic follicular thyroid cancer.  In addition to having her thyroid removed, she also underwent total hip replacement.  All this while raising three small children.  Treatment of her lymphoma included a chemotherapy regimen of adriamycin, bleomycin, vinblastine and dacarbzin.  Her treatment for thyroid cancer featured radioactive iodine.  Bethany credits oxygen therapy for helping her to become free of thyroid cancer and these maintains her health with levothyroxine.   Bethany cannot tell you exactly when she first detected in the vicinity of her thyroid.  It had been there for years when her mother visited, saw the lump and insisted she seek medical attention.  This led to a series of scans and the discovery of a second lump near her clavicle.  A biopsy of the lump on her collarbone resulted in a diagnosis of Hodgkin lymphoma in the Autumn of 2022, while the biopsy of the lump on her thyroid came back as "indeterminant."  Bethany's care team said it would turn its attention to the thyroid lump after addressing her lymphoma diagnosis.   She was placed on a six-month regimen of ABVD chemotherapy, which included adriamycin, bleomycin, vinblastine and dacarbazine.  Bethany suffered many of the usual side effects tied to chemo, including fatigue, nausea and hair loss.  The latter forced her to cut her hair short and then the purchase of a half dozen wigs of different colors.    Bethany attained survivorship from Hodgkin lymphoma, but halfway through her chemo, she underwent a PET scan, which showed two lesions, one on her C5 vertebrae and one on hip.  She underwent a biopsy on the lump on her thyroid in the Spring of 2023, which not only indicated follicular thyroid cancer, but that it had metastasized to the bones in her vertebrae and right hip.    Bethany had to undergo a thyroidectomy and because was eating away at her right hip, it, too, had to be removed.   In September 2023, she began a three-dose regimen of radioactive iodine, which forced her to be kept in isolation.  She was given another CT scan that revealed that cancer was in twelve places in her bones.   Bethany said the pain of her hip replacement exceeded that of three times giving birth without painkillers.  She says she is able to walk just fine these days, walking that includes her love for hiking, and her lack of a thyroid is successfully addressed with levothyroxine, which replaces the hormones lost when her thyroid was removed.   Bethany Smith has experienced the physical toll of her two cancer journeys, but then and now, she deals with everything that has come her way with her natural and boundless sense of optimism.   Additional Resources:   Bethany's app: https://www.stillcancercompanion.com   Bethany's YouTube channel: Bethany Smith Cancer          

In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Pierre-Yves Dumas and Samik Basu on their latest articles published in Blood. Dr. Dumas talks about "Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy" where the team was able to identify that ultra-low-burden FLT3-ITD microclones are associated with higher relapse risk and inferior relapse-free survival. Their work encourages the evaluation of FLT3 inhibitor strategies. Dr. Basu discusses "CD19 CAR T-cell therapy is feasible for patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial". In four patients, the treatment was well tolerated and supported CAR T-cell expansion and persistence, challenging the need for lymphodepletion and supporting chemotherapy-free approaches in autoimmune disease.

In this episode of Hema Now, Megan Melody speaks about the evolution of CAR-T cell therapy and its impact on lymphoma care. She explores the major advances that have transformed outcomes for patients with relapsed and refractory disease, the unanswered questions shaping current research, and the practical challenges of building successful cellular therapy programmes. The conversation also covers equitable access to treatment, the role of quality standards and accreditation, personalised approaches to CAR-T therapy, and the importance of physician leadership and mentorship in shaping the future of academic haematology. Timestamps:   00:00 – Introduction   01:13 – Journey into Haematology and Lymphoma   04:19 – Major Advances in CAR-T   06:00 – Unanswered Questions After CAR-T   07:45 – Building Successful Cellular Therapy Programmes   09:06 – Improving Access to CAR-T   12:55 – Evolving Standards in Cellular Therapy   14:16 – Towards Personalised CAR-T Treatment   16:00 – Physician Leadership in Academic Medicine   17:10 – Career Advice for Future Specialists   19:02 – Future Directions in Cellular Therapy 

BloodCancerTalks: ASCO/EHA 2026 Lymphoma Round-Up with Dr. Thomas LewGuest: Dr. Thomas Lew, Peter MacCallum Cancer Centre (Melbourne, Australia) — hematologist specializing in lymphoid malignancies.In this episode, we break down the biggest lymphoma and CLL data from ASCO and EHA 2026 (Chicago and Stockholm), covering mantle cell lymphoma genomics, bispecific antibodies in DLBCL and follicular lymphoma, a practice-changing (or not) CNS prophylaxis study, transplant-eligible relapsed DLBCL, fixed-duration BTK/BCL2 combinations in CLL, and the first in vivo CAR T data in lymphoma.1. TRIANGLE: TP53-Mutated MCL Molecular Subgroup AnalysisMolecular subgroup data from the practice-shaping TRIANGLE trial presented by Dr. Marta Grau.Discussion: Where TP53-mutated MCL stands today, and whether ibrutinib-containing regimens are changing the natural history of this historically dismal subgroup.2. EPCORE DLBCL-1: Epcoritamab vs. Chemotherapy in R/R DLBCLRandomized phase 3 trial (n=483) of bispecific antibody epcoritamab vs. investigator's choice chemotherapy (72% R-GemOx, 28% BR) in second-line-or-later, transplant-ineligible R/R DLBCL, presented by Prof. Chris Fox.Discussion: A PFS benefit without an OS signal, set against a meaningfully higher infection-related mortality — what this means for patient selection and infection mitigation strategies.3. CNS Prophylaxis in Ultra-High-Risk DLBCL: Does HD-MTX Help?Pooled analysis of two large multicenter retrospective cohorts (n=1,923 ultra-high-risk patients — CNS-IPI 5–6, testicular/renal/adrenal/breast involvement, or ≥3 extranodal sites), presented by Dr. Matt Wilson (Glasgow) and simultaneously published in JCO. Discussion: Whether these data close the door on routine HD-MTX in ultra-high-risk DLBCL, and if any subgroup still warrants prophylaxis.4. Pola-R-ICE: A Negative Trial in Transplant-Eligible R/R DLBCLRandomized phase 3 study (4 European cooperative groups; n=294) of polatuzumab vedotin added to R-ICE in transplant-eligible R/R DLBCL, with ASCT/alloSCT/CAR-T permitted as consolidation.Discussion: Why this trial missed, and what it tells us about the ceiling of intensive salvage chemo-immunotherapy platforms in the CAR-T era.5. BRUIN-CLL-322: Fixed-Duration Pirtobrutinib + Venetoclax-Rituximab in R/R CLLRandomized phase 3 trial (n=639) of fixed-duration pirtobrutinib (non-covalent BTKi) plus venetoclax-rituximab (PVR) vs. venetoclax-rituximab (VR, the MURANO-based control) in second-line-or-later R/R CLL.6. SOUNDTRACK-F1: Surovatamig (CD19 Bispecific) Safety Run-In in Untreated Follicular LymphomaSafety run-in from a randomized trial (surovatamig vs. chemoimmunotherapy) in untreated FL meeting GELF criteria, presented by Prof. Chan Cheah — building on EPCORE-FL-1 data presented at ASH.Discussion: How this CD19-directed bispecific compares to CD20-targeting agents in frontline FL.7. LB2501: First In Vivo CAR T Data in B-Cell LymphomaLate-breaking data from Dr. Lei Fan and Legend Biotech on LB2501, an in vivo CD19/CD20 dual-targeted CAR T therapy — a third-generation, self-inactivating, replication-incompetent lentiviral vector that generates CAR T cells directly in vivo, without lymphodepletion. Builds on the in vivo CAR T myeloma data first presented at ASH and updated at EHA.Discussion: What these very early but striking data suggest about the feasibility of in vivo CAR T generation in lymphoma, and how it might reshape access to cellular therapy.BloodCancerTalks is co-hosted by Rajshekhar Chakraborty,  Ashwin Kishtagari and Eddie Cliff. Subscribe wherever you get your podcasts. 

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Hanny Al-Samkari and Xin Zhou on their latest articles published in Blood. This episode highlights two important advances in hematology: the first report from the CHORUS registry for hereditary hemorrhagic telangiectasia (HHT) presented by Dr. Al-Samkari and also the introduction of the ASH Hematomics (ASHOP) platform for integrative genomic data analysis presented by Dr. Zhou. The CHORUS registry reveals that HHT is a progressive, underrecognized inherited bleeding disorder with a substantial burden of recurrent bleeding, iron deficiency, arteriovenous malformations, and life-threatening complications, while emphasizing the need for earlier diagnosis and the development of targeted therapies. The second presentation introduces ASHOP, an open-access platform that enables researchers to explore and integrate large-scale clinical and genomic datasets, facilitating discoveries in leukemia and other hematologic diseases through advanced analytical tools. Together, these studies demonstrate how comprehensive patient registries and innovative data-sharing resources are advancing precision medicine, improving disease understanding, and accelerating future research across hematology.

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Haris Sohail and Lucas Kühne on their latest articles published in volume 147 issue 21 of Blood. In this CME article titled, "Retrospective, Real-World Study of IV Iron Use to Treat Iron deficiency Anemia During Acute Infection",  Sohail et al show that IV iron given during acute infection with iron deficiency anemia is associated with improved 14-day and 90-day survival as well as hemoglobin recovery. Although this report has the limitations of a retrospective study, these findings challenge current practice and support randomized trials that include patients with infection. In "Revisiting Clinical Response and Refractoriness in Immune Thrombotic Thrombocytopenic Purpura", Kühne et al show in a multicenter registry study of 204 patients that refractoriness during caplacizumab treatment in immune TTP is uncommon and, when observed, is typically associated with confounding clinical factors. These findings underscore the importance of careful clinical reassessment and evaluation for alternative etiologies in patients with delayed platelet recovery, rather than attributing such cases to true treatment resistance.

What if the way back to health isn't found in fighting harder… but in reconnecting with nature? After being diagnosed with leukemia and lymphoma, Dean Hall made a decision that left even his doctors shaking their heads. He swam 187 miles of Oregon's longest river. He embraced a practice known as forest bathing. Today, Dean is in remission! Coincidence? Conviction? Or is there more to this story? In this week's episode, Autumn and Dean explore a radically different conversation about healing, purpose, grief, the nervous system, and our relationship with the natural world God created. This conversation may completely change the way you think about striving for health, supporting the body's ability to heal, and God's fingerprints woven throughout creation.

In this episode of the Oncology Brothers podcast, we tackled two real-world challenging cases in diffuse large B-cell lymphoma (DLBCL) alongside two lymphoma experts — Dr. Matthew Lunning from the University of Nebraska and Dr. Gilles Salles from Memorial Sloan Kettering Cancer Center. The central question: when faced with relapsed or transformed aggressive B-cell lymphoma, how do you choose between CAR-T cell therapy and bispecific antibodies, and how do you get patients through this safely?   Key topics discussed included: The role of CAR-T cell therapy in early relapsed DLBCL based on ZUMA-7 and TRANSFORM trial data, and practical strategies for bridging and holding therapy pre- and post-apheresis to safely deliver treatment. A comparison of axicabtagene ciloleucel versus lisocabtagene maraleucel in terms of efficacy, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) rates, and outpatient feasibility. Management of transformed follicular lymphoma to double-hit DLBCL in the third-line setting, including the role of glofitamab, mosunetuzumab, polatuzumab, and epcoritamab as bridges to CAR-T cell therapy. The importance of early partnership between community oncologists and tertiary care centers to ensure patients access CAR-T and bispecific therapies in a timely manner. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Join us for this expert discussion on navigating the complex treatment landscape of relapsed and transformed aggressive B-cell lymphoma. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology! #DLBCL, #CARTTherapy, #BispecificAntibodies, #Hematology, #OncologyBrothers  

In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Kirsty Hillier and Marco Ruella on their latest articles published in Blood. For "Predicting Development of Pediatric Chronic Immune Thrombocytopenia at Disease Onset Using a Statistical Risk Model", Dr. Hillier shares the potential benefits of incorporating this new model to enhance the care of the 1 in 4 patients who develop chronic ITP. As an alternative to current guidelines which advise providers to "wait and see", this online model determines patients who are at risk for chronic ITP, allowing for providers to make informed decisions on their continued care. In "Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies", Dr. Ruella explains how the treatment of T-cell neoplasms is limited by a lack of discriminating T-cell antigens that allow for effective antitumor responses while preventing CAR T-cell fratricide. The team found that CD2 was a viable target, especially combined with a novel PD-1:CD2 switch receptor to remedy dysfunction caused by CD2 deletion.  

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Carla Casulo, a world-renowned clinician and researcher from the University of Rochester, to discuss the latest highlights from the European Hematology Association (EHA) 2026 conference, focusing on lymphoma.   Join us as we dived into four pivotal studies: frontMIND: We explored the efficacy of tafasitamab plus lenalidomide with R-CHOP compared to R-CHOP alone in frontline treatment for diffuse large B-cell lymphoma (DLBCL). Discover the implications of improved progression-free survival (PFS) and the associated toxicities. POLAR-BEAR: We discussed the head-to-head comparison of mini–pola-R-CHP versus mini–R-CHOP in frail or elderly patients with DLBCL. What does this mean for the use of polatuzumab in clinical practice? High-Dose Methotrexate for CNS Prophylaxis: Learn about the significant findings that suggest high-dose methotrexate may not improve outcomes in high-risk patients, potentially changing treatment protocols. EPCOR FL1: We covered the approval of epcoritamab in relapsed and refractory follicular lymphoma, highlighting its benefits and the importance of time-limited therapy.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o   Follow us on social media: X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/  Tune in for an insightful discussion on these important studies and their potential impact on clinical practice. Don't forget to subscribe for more updates on conference highlights, FDA approvals, and treatment algorithms!

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Heinz Zoller and Raul Ribeiro on their latest articles published in Blood. Dr. Zoller discusses "Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia", and how these findings support consideration of alternative IV iron formulations that provide similar efficacy without risk of skeletal complications.  Dr. Ribeiro discusses "A low-versus standard-dose regimen an induction for AML: a multicenter, randomized noninferiority trial" and how the low-dose regimen is associated with fewer toxicities, faster hematologic recovery, and reduced health care costs, suggesting a feasible treatment strategy for resource-limited settings.

Send us Fan MailSteve Olsen is a retired dentist, a high-performance coach, and a walking miracle. Diagnosed simultaneously with stage four lymphoma, stage one kidney cancer, and total kidney failure requiring dialysis, Steve was handed a grim medical prognosis. Refusing to accept the “probable,” he relentlessly focused on the “possible”. By combining traditional medical interventions with advanced mindset techniques, NuCalm neuroacoustic technology, and deep faith, Steve achieved complete remission within a year. Today, through his platform OptimalPerformance.cc, he coaches everyone from patients to race car drivers on how to control their thoughts, enter the flow state, and live a life of victory.Key Discussion Highlights & TakeawaysThe Cancer Diagnosis: How Steve processed the devastating news of stage 4 lymphoma and kidney failure, and why he immediately rejected the standard terminal timeline.Possible vs. Probable: The crucial mindset shift required to survive critical illness, and why Steve tells patients to actively seek out stories of people who beat the odds.The NuCalm Protocol: How Steve used binaural beats and the NuCalm system to safely guide his brain into the Gamma flow state, allowing him to visualize his immune system destroying cancer cells.Respond, Don't React: Why reacting is an emotion-driven survival reflex, whereas responding is a deliberate, calm, and practiced choice that lowers the body's toxic stress load.The Black Door: A powerful illustration of why human beings often choose the comfort of known suffering over the fear of the unknown—even when the unknown leads to freedom Key Timestamps & Moments of Gold00:00:00 – Episode Intro & MyPillow Mega Sale00:02:40 – Welcome Steve Olsen: The Importance of Mindset00:05:00 – Steve's Early Life, Photojournalism, and Coaching Roots00:09:10 – Facing Stage 4 Lymphoma, Kidney Cancer, and Dialysis00:13:30 – Fixed vs. Growth Mindset and the Power of Definition00:15:10 – The Bernie Siegel Story: How Words Can Kill or Heal00:20:40 – The Gamma Brain Wave: Visualizing Healing and Flow State00:23:00 – Using NuCalm to Warp Time Perception and Relieve Stress00:30:20 – Stress: The Silent Killer and the “Respond vs. React” Framework00:35:00 – Victor Frankl and Choosing Your Response in the Darkest Times00:38:00 – Rebuilding Concrete Hope When All Seems Lost00:44:00 – Entering the Gamma State Safely with Binaural Beats00:50:00 – Connecting with Steve Olsen at optimalperformance.cc00:54:00 – Final Thoughts, Taking Action, and Episode Wrap-UpWebsite: https://OptimalPerformance.cc (not .com)More Info: https://www.copingconqueringcancer.comSupport the showTHE NOT-SO-FINE-PRINT DISCLAIMER: While we are very thankful for all of our guests, please understand that we do not necessarily share or endorse the same beliefs, worldviews, or positions that they may hold. We respectfully agree to disagree in some areas, and thank God for the blessing and privilege of free will.For more Remarkable Episodes, Inspiration, and Motivation, please visit https://davidpasqualone.com/remarkable-people-podcast/ now!

This week we welcome the boy Foster Moreau back to the pod, and it's safe to say Foster has had one of the craziest offseasons of all NFL Players. The boys immediately get some hot takes about some actor as well as get into some conspiracy theories. Foster shares some stories of his time at LSU about different bars he used to go to and just the town itself. The boys then get into Foster’s crazy offseason. He was diagnosed with Hodgkin's Lymphoma in March while on a visit to the Saints. He shares the story of how he found out from his physical and the exact type of cancer he was diagnosed with. Foster gets into what it was like telling his family and friends and how difficult it was. The boys then lighten the mood as they get into how he has officially been signed to the New Orleans Saints and is reunited with Derek Carr. The boys end the pod with a legendary Tier Talk of best iPhone games. Foster was super open with the boys and it is no doubt a must listen. Enjoy.See omnystudio.com/listener for privacy information.

EVEN MORE about this episode!Join Julie Ryan for another inspiring live episode as callers from around the world seek answers about chronic health conditions, grief, anxiety, family relationships, and spiritual guidance.Julie performs real-time medical intuitive scans for concerns including hormone imbalances, inflammation, eczema, pancreatic cancer recovery, neuropathy, back injuries, macular degeneration, and mold sensitivity while offering practical wellness suggestions and energetic healing. Along the way, she shares actionable insights on nutrition, supplements, bioidentical hormones, and supporting the body's natural healing abilities.The episode also features touching spirit communication, including a heartfelt message from a caller's late girlfriend and powerful guidance for navigating loss, family estrangement, and emotional healing. Whether you're searching for health answers, spiritual comfort, or a deeper understanding of your body's wisdom, this episode offers hope, healing, and practical guidance you can apply to your own life.Episode Chapters:(0:02:42) - Helen from England: Family Estrangement and Telepathic Communication(0:05:19) - Greg from Atlanta: Connecting with His Deceased Girlfriend Karen(0:14:10) - Nina from New Jersey: Body Scan for Inflammation, Hormones, and Weight(0:19:18) - Nancy from Oklahoma City: Eczema, Leaky Gut, and Yeast Overgrowth(0:23:21) - Eileen from New Jersey: Squirrel Incident, Bulging Disc, and Osteoporosis(0:33:08) - Mary from Florida: Pancreatic Cancer Recovery and Neuropathy Healing(0:44:27) - Karen from Chicago: Healing for Husband Mark's Non-Hodgkin's Lymphoma(0:50:14) - Medical Intuitive Training Class Winner(0:54:00) - Sarah: How to Go Within, Meditate, and Ground(0:57:13) - Yohannes from Cambridge: Healing for His Mother's Macular Degeneration(1:04:56) - Azura from Tulum: Mold Sensitivity and Finding Safe Housing➡️ Subscribe to Ask Julie Ryan YouTube➡️ Julie's Intuitive Trainings✏️ Ask Julie a Question!

Jonathon Cohen, MD, MS When you hear the word “aggressive,” it can feel overwhelming, but in diffuse large B-cell lymphoma (DLBCL), it can also point to something encouraging – a potential cure. In this episode, we speak with Dr. Jonathon Cohen, of Winship Cancer Institute in Atlanta, GA, about what a DLBCL diagnosis really means, from how this common type of non-Hodgkin lymphoma is identified to current treatment options and emerging therapies. We explain what patients and families need to know about side effects. We also look at new treatments, including CAR T-cell therapy and bispecific antibodies, and the importance of open communication with your care team. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: Diffuse large B-cell lymphoma CAR T-cell therapy Stem cell transplantation Bispecific antibodies (immunotherapy fact sheet) Clinical Trial Support Center Additional Blood Cancer United Support Resources: Information Specialists Young Adult Resources Young Adult Online Chat Financial support Free Nutrition Consultations Free telephone/web patient programs SHARE web series Online videos Free booklets Patient Community Support groups Caregiver support Caregiver Workbook Survivorship Workbook Advocacy and Public Policy Mental Health Resources Episode supported by Genmab US, Inc.The post Diffuse Large B-Cell Lymphoma (DLBCL): Breaking Down an Aggressive Lymphoma first appeared on The Bloodline with Blood Cancer United Podcast.

Drs. Tina Lockwood and Stacy Gray share the newly released evidence-based guideline on circulating tumor DNA (ctDNA) testing from ASCO. They highlight recommendations on when ctDNA testing should be offered—including scenarios where tissue biopsies are challenging, unsafe, or unavailable in time to guide management—and explicitly outline situations where testing should not be utilized. They dive into the evidence evaluating ctDNA for treatment selection, molecular residual disease (MRD), and response monitoring across solid tumors and lymphoma. Drs. Lockwood and Gray explain the importance of balancing ctDNA's high specificity with its moderate sensitivity. They also touch on outstanding questions, including standardizing definitions for MRD, disease-specific applications, and the use of multi-cancer early detection (MCED) screening.  Read the full guideline, "Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline" at www.asco.org/molecular-testing-and-biomarkers-guidelines" LINK TO FULL TRANSCRIPT

Yah Welcome Wednesday It has been a question that's been hitting our inbox since we started and today we answer it, today we discuss the idea of welcoming a female voice on the show!... New Zealand has always been portrayed as a sporting country but is that really the case?... The Shifters are given a chance to ask us anything and well, we have to answer!... The Speights Men's Den is a powerful one, as Shift Nation. We have the opportunity to come together and help one of our own, Mike... Mike has been battling Non -Hodgkin's Lymphoma since March 2025 and is in need of treatment that requires him to go overseas but the thing is, it isn't cheap... Shift Nation let's do what we do best and come together to help, but the time to help Mike is now! (Link Below To Donate) Shift Nation, Any donations are more than appreciated! If you would like to donate to help Mike, tap the link below! https://givealittle.co.nz/cause/help-mikey-reach-his-car-t-therapy-overseas Hit that link below to stay caught up with anything and everything TMS. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.facebook.com/groups/3394787437503676/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ We dropped some merch! Use TMS for 10% off. Here is the link: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://youknowclothing.com/search?q=tms⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Thank you to the team at Chemist Warehouse for helping us keep the lights on, here at The Morning Shift... ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.chemistwarehouse.co.nz/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 00:00 - INTRO 2:44 - CHECK IN (WORLD CUP FEVER) 11:52 - DAILY BREAD 19:30 - SHIFTERS ASK, WE ANSWER 38:03 - SPEIGHTS MEN'S DEN 44:19 - OUTRO Learn more about your ad choices. Visit megaphone.fm/adchoices

Friday - Clark Stinks day! Christa shares Clark Stinks posts with Clark. Submit yours at Clark.com/ClarkStinks.    Also, while many of us use fitness trackers to count steps or monitor sleep, the latest data shows some of these devices are evolving into genuine lifesavers. Clark has worn a Garmin for twenty years and a Samsung smartwatch, but the Oura Ring has truly impressed him and for good reason, as new findings indicate.   Clark Stinks: Segments 1 & 2 Oura Reports: Segment 3 Ask Clark: Segment 4 Mentioned on the show: Is Turo Legit? 5 Things To Know Before You Use It 5 of Clark Howard's Most Extreme Frugal Hacks What Is Umbrella Insurance and Do You Need It? - Clark Howard The Insurance Policies You Need (and Some You Don't) What Age Are Americans Actually Starting Social Security? Term Life vs. Whole Life Insurance: Understanding the Difference Oura Ring Helps Uncover 'Multiple Cases of Lymphoma,' Says Its Chief Medical Officer Axios: Finish Line: The quiet rise of "prescribing connection" 4 Ways To Stop Junk Mail - Clark Howard How To Choose the Best Charities for Your Donations - Clark Howard Memorial Day 2026: Facts, Meaning & Traditions Clark.com resources: Episode transcripts Community.Clark.com  /  Ask Clark Clark.com daily money newsletter Consumer Action Center Free Helpline: 636-492-5275 Learn more about your ad choices. Visit megaphone.fm/adchoices

Link Up w/The Morning Sickness Digitally All Over:Instagram: @hms_98_official, @bosskupd, @bretvesely, @dickToledoX/Twitter: @HMSon98, @DickToledo, @bretveselyFacebook: @HMSKUPDYouTube: @hmspodcast9320, @98kupdRequest/Call in/Wakeup Song line:(IN AZ) 602.585.9800More HMS: holmbergpodcast.com, 98kupd.comEmail: dtoledo@98kupd.com, bvesely@98kupd.com, bbogen@98kupd.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.